(SPRO) Spero Therapeutics - Overview
Stock: Tebipenem HBr, SPR720
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 59.4% |
| Relative Tail Risk | -18.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.95 |
| Alpha | 166.37 |
| Character TTM | |
|---|---|
| Beta | 0.474 |
| Beta Downside | 1.928 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.28% |
| CAGR/Max DD | 0.15 |
Description: SPRO Spero Therapeutics January 03, 2026
Spero Therapeutics (NASDAQ: SPRO) is a Cambridge-based clinical-stage biotech that targets multi-drug-resistant bacterial infections and rare diseases in the U.S. Its lead assets are Tebipenem HBr, an oral carbapenem in Phase 3 for complicated urinary-tract infections (including pyelonephritis), and SPR720, a novel oral candidate for first-line treatment of nontuberculous mycobacterial pulmonary disease. The company leverages strategic licenses with Meiji Seika (Tebipenem), Everest Medicines (SPR206 in Greater China, South Korea, and Southeast Asia) and Vertex Pharmaceuticals (patents covering SPR720/SPR719). Founded in 2013, SPRO operates within the Biotechnology sub-industry.
As of the most recent 10-Q, Spero reported roughly $85 million in cash and marketable securities, giving it an estimated 12-month runway at current burn rates. The global MDR bacterial infection market is projected to exceed $30 billion by 2028, while the FDA’s QIDP (Qualified Infectious Disease Product) pathway offers priority review and extended exclusivity-both strong economic tailwinds for oral antibiotics like Tebipenem. Additionally, SPR720 benefits from a partnership with Vertex that could accelerate regulatory filing and commercial rollout, potentially addressing a $5 billion NTM disease market.
For a deeper, data-driven look at SPRO’s valuation and risk profile, you might find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -43.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.51 > 0.02 and ΔFCF/TA -38.11 > 1.0 |
| NWC/Revenue: 108.1% < 20% (prev 81.40%; Δ 26.73% < -1%) |
| CFO/TA -0.51 > 3% & CFO -27.7m > Net Income -43.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.3m) vs 12m ago 3.98% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 37.78% > 50% (prev 75.02%; Δ -37.23% > 0%) |
| Interest Coverage Ratio: -4.29 > 6 (EBITDA TTM -45.1m / Interest Expense TTM 8.24m) |
Altman Z'' -15.00
| A: 0.71 (Total Current Assets 52.3m - Total Current Liabilities 13.6m) / Total Assets 54.2m |
| B: -8.91 (Retained Earnings -482.6m / Total Assets 54.2m) |
| C: -0.37 (EBIT TTM -35.3m / Avg Total Assets 94.7m) |
| D: -17.43 (Book Value of Equity -482.5m / Total Liabilities 27.7m) |
| Altman-Z'' Score: -45.17 = D |
Beneish M -3.63
| DSRI: 0.13 (Receivables 2.46m/53.3m, Revenue 35.8m/101.4m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 2.50 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 0.35 (Revenue 35.8m / 101.4m) |
| TATA: -0.30 (NI -43.8m - CFO -27.7m) / TA 54.2m) |
| Beneish M-Score: -3.63 (Cap -4..+1) = AAA |
What is the price of SPRO shares?
Over the past week, the price has changed by +10.50%, over one month by -3.59%, over three months by +1.26% and over the past year by +180.32%.
Is SPRO a buy, sell or hold?
- StrongBuy: 0
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SPRO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4 | 65.3% |
| Analysts Target Price | 4 | 65.3% |
| ValueRay Target Price | 2.5 | 1.7% |
SPRO Fundamental Data Overview February 02, 2026
P/B = 4.657
Revenue TTM = 35.8m USD
EBIT TTM = -35.3m USD
EBITDA TTM = -45.1m USD
Long Term Debt = 3.35m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.90m USD (from shortTermDebt, last quarter)
Debt = 3.35m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -45.3m USD (from netDebt column, last quarter)
Enterprise Value = 78.1m USD (123.4m + Debt 3.35m - CCE 48.6m)
Interest Coverage Ratio = -4.29 (Ebit TTM -35.3m / Interest Expense TTM 8.24m)
EV/FCF = -2.82x (Enterprise Value 78.1m / FCF TTM -27.7m)
FCF Yield = -35.43% (FCF TTM -27.7m / Enterprise Value 78.1m)
FCF Margin = -77.37% (FCF TTM -27.7m / Revenue TTM 35.8m)
Net Margin = -122.6% (Net Income TTM -43.8m / Revenue TTM 35.8m)
Gross Margin = unknown ((Revenue TTM 35.8m - Cost of Revenue TTM 108.2m) / Revenue TTM)
Tobins Q-Ratio = 1.44 (Enterprise Value 78.1m / Total Assets 54.2m)
Interest Expense / Debt = 28.68% (Interest Expense 961.0k / Debt 3.35m)
Taxrate = 21.0% (US default 21%)
NOPAT = -27.9m (EBIT -35.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.83 (Total Current Assets 52.3m / Total Current Liabilities 13.6m)
Debt / Equity = 0.13 (Debt 3.35m / totalStockholderEquity, last quarter 26.5m)
Debt / EBITDA = 1.00 (negative EBITDA) (Net Debt -45.3m / EBITDA -45.1m)
Debt / FCF = 1.64 (negative FCF - burning cash) (Net Debt -45.3m / FCF TTM -27.7m)
Total Stockholder Equity = 34.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.31% (Net Income -43.8m / Total Assets 54.2m)
RoE = -125.9% (Net Income TTM -43.8m / Total Stockholder Equity 34.8m)
RoCE = -92.52% (EBIT -35.3m / Capital Employed (Equity 34.8m + L.T.Debt 3.35m))
RoIC = -80.12% (negative operating profit) (NOPAT -27.9m / Invested Capital 34.8m)
WACC = 8.06% (E(123.4m)/V(126.7m) * Re(7.66%) + D(3.35m)/V(126.7m) * Rd(28.68%) * (1-Tc(0.21)))
Discount Rate = 7.66% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 2.94%
Fair Price DCF = unknown (Cash Flow -27.7m)
EPS Correlation: 33.76 | EPS CAGR: 64.08% | SUE: 0.65 | # QB: 0
Revenue Correlation: 45.32 | Revenue CAGR: 2.84% | SUE: 0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.18 | Chg30d=+0.020 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.67 | Chg30d=+0.655 | Revisions Net=+0 | Growth EPS=+770.0% | Growth Revenue=-96.9%